(Q42542786)

English

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

scientific article published on 29 August 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 November 2017

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial (English)

1 reference

Europe PubMed Central

2 November 2017

0 references

circulatory system

1 reference

based on heuristic

inferred from title

author name string

Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators

1

1 reference

Europe PubMed Central

2 November 2017

S Yusuf

2

1 reference

Europe PubMed Central

2 November 2017

K Teo

3

1 reference

Europe PubMed Central

2 November 2017

C Anderson

4

1 reference

Europe PubMed Central

2 November 2017

J Pogue

5

1 reference

Europe PubMed Central

2 November 2017

L Dyal

6

1 reference

Europe PubMed Central

2 November 2017

I Copland

7

1 reference

Europe PubMed Central

2 November 2017

H Schumacher

8

1 reference

Europe PubMed Central

2 November 2017

G Dagenais

9

1 reference

Europe PubMed Central

2 November 2017

P Sleight

10

1 reference

Europe PubMed Central

2 November 2017

language of work or name

0 references

publication date

29 August 2008

1 reference

Europe PubMed Central

2 November 2017

1 reference

Europe PubMed Central

2 November 2017

372

1 reference

Europe PubMed Central

2 November 2017

1174-1183

1 reference

Europe PubMed Central

2 November 2017

9644

1 reference

Europe PubMed Central

2 November 2017

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Beta blockade during and after myocardial infarction: an overview of the randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of ramipril on the incidence of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiotensin receptor blockers and myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Ramipril and the development of diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961242-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(08)61242-8

1 reference

Europe PubMed Central

2 November 2017

1 reference

Europe PubMed Central

2 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42542786&oldid=1961268774"